Investigational drug · Phase 2
TL-895
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Myelofibrosis, Primary Myelofibrosis, Post-PV MF.
Phase 2Last checked: Nov 19, 2026Latest source record: Feb 21, 2023 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
7
Any phase or sponsor naming "TL-895"
First trial start
2022
Jun 9, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TL-895", any sponsor or status.
Conditions studied
As listed on its trial records.
- Myelofibrosis
- Primary Myelofibrosis
- Post-PV MF
- Post-ET Myelofibrosis
Approved drugs for the same conditions: Myelofibrosis · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "TL-895" as an intervention, largest first.
- Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL SubjectsPivotal-lookingStatus unknown
Telios Pharma, Inc.Industry
NCT02825836 · 130 participants (planned) · Start Aug 26, 2016 · Primary completion Dec 1, 2024
Drug: TL-895; Navtemadlin · For: Relapsed/Refractory B Cell Malignancies; Mantle Cell Lymphoma and Diffuse Large B Cell Lymphoma; Chronic Lymphocytic Leukemia and 2 more
Sites: Columbus, Ohio; Germantown, Tennessee; Debrecen, Hungary · 17 sites in all
- Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic MastocytosisPivotal-lookingStatus unknown
Telios Pharma, Inc.Industry
NCT04655118 · 121 participants (planned) · Start Oct 22, 2020 · Primary completion Jun 30, 2025
Drug: TL-895; Placebo · For: Myelofibrosis; Indolent Systemic Mastocytosis
Sites: Aurora, Colorado; Rochester, Minnesota; Canton, Ohio · 52 sites in all
- KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MFPivotal-lookingStatus unknown
Kartos Therapeutics, Inc.Industry
NCT04640532 · 116 participants (planned) · Start Nov 17, 2020 · Primary completion May 11, 2022
Drug: KRT-232; TL-895 · For: Myelofibrosis; Post-PV MF; Post-ET Myelofibrosis and 1 more
Sites: Birmingham, Alabama; Whittier, California; Lake City, Florida · 37 sites in all
Telios Pharma, Inc.Industry
NCT05280509 · 70 participants (planned) · Start Jun 9, 2022 · Primary completion Oct 2025
Drug: TL-895; Ruxolitinib · For: Myelofibrosis; Primary Myelofibrosis; Post-PV MF and 1 more
Sites: Birmingham, Alabama; Canton, Ohio; Cincinnati, Ohio · 19 sites in all
- Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve MyelofibrosisStatus unknown
Kartos Therapeutics, Inc.Industry
NCT04878003 · 52 participants (planned) · Start Apr 13, 2021 · Primary completion May 2024
Drug: KRT-232; TL-895 · For: Primary Myelofibrosis (PMF); Post-Polycythemia Vera Myelofibrosis (Post-PV-MF); Post-Essential Thrombocythemia Myelofibrosis (Post-ET-MF)
Sites: Glendale, California; Whittier, California; Canton, Ohio · 29 sites in all
- TL-895 and KRT-232 Study in Acute Myeloid LeukemiaStatus unknown
Telios Pharma, Inc.Industry
NCT04669067 · 18 participants · Start Mar 31, 2021 · Primary completion Nov 2024
Drug: TL-895; KRT-232 · For: Acute Myeloid Leukemia
Sites: Los Angeles, California; Orange, California; Augusta, Georgia · 35 sites in all
Telios Pharma, Inc.Industry
NCT04419623 · 7 participants · Start Jul 9, 2020 · Primary completion Sep 22, 2020
Drug: TL-895 · For: COVID-19; Sars-CoV2; Cancer and 3 more
Sites: Augusta, Georgia; Columbus, Ohio
Newest research
PubMed records naming it or its code names, newest first.
- Drug-Drug Interaction Liabilities with BTK Inhibitor TL-895.
Stromatt JC, Ahmed EA, Drabison T, et al. · Cancer Res Commun 2025
- New treatments for systemic mastocytosis in 2025.
Costanzo G, Marzio V, Cavaglià E, et al. · Curr Opin Allergy Clin Immunol 2025
- Preclinical evidence for the effective use of TL-895, a highly selective and potent second-generation BTK inhibitor, for the treatment of B-cell malignancies.
Goodstal SM, Lin J, Crandall T, et al. · Sci Rep 2023
Also in development for Myelofibrosis
- ElriterceptTAK-226, KER-050Phase 36 trials
Takeda · Myelodysplastic Syndromes, Myelofibrosis, Anemia
- BomedemstatMK-3543, IMG-7289Phase 35 trials
Merck & Co. · Polycythemia Vera, Essential Thrombocythemia, Thrombocythemia, Essential
- RovadicitinibTQ05105Phase 35 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chronic Graft Versus Host Disease, Myelofibrosis, Graft-versus-host Disease
- KRT-232NavtemadlinPhase 34 trials
Kartos Therapeutics, Inc. · Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
- PelabresibDAK539, CPI-0610Phase 34 trials
Novartis · Myelofibrosis, Primary Myelofibrosis, Primary Myelofibrosis (PMF)
- BMS-986158Phase 22 trials
Bristol Myers Squibb · Myelofibrosis, Multiple Myeloma
- DISC-0974Phase 22 trials
Disc Medicine, Inc · Anemia, Inflammatory Bowel Disease (IBD), Inflammatory Bowel Disease (IBD); Anemia
- amsulostatPXS-5505Phase 21 trial
Syntara · Myelofibrosis, Primary Myelofibrosis (PMF), Post- Essential Thrombocythemia Myelofibrosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.